Evidence map›Paper›PMID 42360715›Full record

ArticleStatistics in medicine2026

A Causal Framework for Evaluating the Total Effect of Strategies Aiming to Expand Screening and to Improve Outcomes.

Joy Z Nakato, Janice Litunya, Brian Beesiga, Jane Kabami, James Ayieko, Moses R Kamya, Gabriel Chamie, Laura B Balzer

Abstract read
In one paragraph

Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Joy Z NakatoDivision of Biostatistics, University of California, Berkeley, CA, USA.ORCID https://orcid.org/0009-0007-8193-4989
Janice LitunyaKenya Medical Research Institute (KEMRI), Kisumu, Kenya.
Brian BeesigaInfectious Disease Research Collaboration (IDRC), Kampala, Uganda.
Jane KabamiInfectious Disease Research Collaboration (IDRC), Kampala, Uganda.
James AyiekoKenya Medical Research Institute (KEMRI), Kisumu, Kenya.ORCID https://orcid.org/0000-0002-0324-4006
Moses R KamyaInfectious Disease Research Collaboration (IDRC), Kampala, Uganda.
Gabriel ChamieDivision of HIV, Infectious Diseases & Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0002-5860-8081
Laura B BalzerDivision of Biostatistics, University of California, Berkeley, CA, USA.ORCID https://orcid.org/0000-0002-3730-410X

Funding

A Multisectoral Strategy to Address Persistent Drivers of the HIV Epidemic in East AfricaU01AI150510 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V, KAMYA, MOSES ROBERT · 2020 to 2025
$23.4M
Innovative strategies to promote biomedical HIV prevention uptake and retention among high-risk adults at drinking venues in Kenya and UgandaR01AA030464 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gabriel Chamie · 2022 to 2026
$3.0M
Mentorship in patient-oriented research to optimize community-based HIV prevention for adults at high-risk of HIV at alcohol drinking venues in East AfricaK24AA031211 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gabriel Chamie · 2023 to 2026
$785k
Targeted Machine Learning to evaluate and optimize HIV prevention strategies in cluster randomized trialsR01MH140685 · NIMH · UNIVERSITY OF CALIFORNIA BERKELEY · PI Laura B Balzer · 2026 to 2026
$760k
NIAAA NIH HHS K24 AA031211NIH HHS K24AA031211NIH HHS R01AA030464NIH HHS R01MH140685NIH HHS U01AI150510
6 · The paper itself

Abstract

For many health conditions, there are highly efficacious treatment and prevention products. Maximizing their impact requires strategies that improve the reach of health screening in order to establish who could benefit. For example, HIV prevention strategies aim to expand risk screening and to improve uptake of pre-exposure prophylaxis (PrEP) among those experiencing risk. Often, these strategies induce changes at the group-level (e.g., health clinics or communities) and are evaluated through cluster randomized trials. This scenario creates a complex, multilevel-mediation-missing data problem for the following reasons: First, the strategy is delivered at the cluster-level, while health screening and outcomes are at the individual-level. Second, the strategy improves health outcomes directly and indirectly through improved health screening. Third, everyone has an "underlying" status, which is only observed among those screened. To formally define the total effect in such settings, we use Counterfactual Strata Effects: causal estimands where the outcome is only relevant for a group whose membership is subject to missingness and/or impacted by the exposure of interest. To identify and estimate the corresponding statistical estimand, we propose a novel extension of Two-Stage targeted minimum loss-based estimation (TMLE). Simulations demonstrate the practical performance of our approach as well as the limitations of existing approaches.

Indexed as

CausalityMass ScreeningComputer SimulationHIV InfectionsHumansModels, StatisticalPre-Exposure ProphylaxisRandomized Controlled Trials as Topiccluster randomized trialscounterfactual strata effectsgroup randomized trialsmediationmissing datascreeningtargeted minimum loss‐based estimation

Identifiers

PMID42360715
PMCPMC13308543

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.